{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:42:59Z","timestamp":1776991379830,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.cgh.2022.08.015","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T09:54:04Z","timestamp":1661421244000},"page":"1050-1060.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Predictors of Placebo Induction Response and Remission in Ulcerative Colitis"],"prefix":"10.1016","volume":"21","author":[{"given":"Emily C.L.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parambir S.","family":"Dulai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-8436","authenticated-orcid":false,"given":"Neeraj","family":"Narula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2022.08.015_bib1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2022.08.015_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2022.08.015_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/ecco-jcc\/jjab135","article-title":"Systematic review and meta-analysis: clinical, endoscopic, histologic and safety placebo rates in induction and maintenance trials of ulcerative colitis","volume":"16","author":"Sedano","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2022.08.015_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.641436","article-title":"The placebo and nocebo responses in clinical trials in inflammatory bowel diseases","volume":"12","author":"Enck","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cgh.2022.08.015_bib5","first-page":"CD011572","article-title":"Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis","volume":"9","author":"Jairath","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2022.08.015_bib6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/ibd\/izy365","article-title":"Factors affecting clinical and endoscopic outcomes of placebo arm in trials of biologics and small molecule drugs in ulcerative colitis: a meta-analysis","volume":"25","author":"Macaluso","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2022.08.015_bib7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cgh.2019.08.025","article-title":"Response to placebo, measured by endoscopic evaluation of Crohn\u2019s disease activity, in a pooled analysis of data from 5 randomized controlled induction trials","volume":"18","author":"Duijvestein","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.08.015_bib8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ecco-jcc\/jjab194","article-title":"Clinical, endoscopic and safety placebo rates in induction and maintenance trials of Crohn\u2019s disease: meta-analysis of randomised controlled trials","volume":"16","author":"Almradi","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2022.08.015_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2022.08.015_bib10","first-page":"317","article-title":"Adalimumab in the treatment of moderate-to-severe ulcerative colitis: ULTRA 2 trial results","volume":"9","author":"Sandborn","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.cgh.2022.08.015_bib11","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2022.08.015_bib13","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2022.08.015_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.08.015_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2013.03.025","article-title":"The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis","volume":"145","author":"Feagan","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.08.015_bib16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00054725-200409000-00026","article-title":"C-reactive protein as a marker for inflammatory bowel disease","volume":"10","author":"Vermeire","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2022.08.015_bib17","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522008114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522008114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:41:07Z","timestamp":1761543667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356522008114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1542356522008114"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2022.08.015","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Placebo Induction Response and Remission in Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the AGA Institute","name":"copyright","label":"Copyright"}]}}